Claims
- 1. A method of treating ulcers or hypersecretion in a mammal which method comprises administering to said mammal in need of such treatment an effective amount of a compound of formula: ##STR18## or a pharmaceutically acceptable salt thereof, wherein --B--B.sup.1 -- represents a chain of formula
- --(CHR.sup.5).sub.n --CHR.sup.6 -- (Ia)
- R represents phenyl, naphthyl or an heteroaryl radical selected from the group pyridyl, thienyl, furyl, thiazolyl, quinolyl, isoquinolyl and indolyl each optionally substituted by not more than three substituents the same or different selected from lower alkylthio, lower alkyl, lower alkoxy, halogen, alkanyloxy of 2 to 7 carbon atoms, lower alkoxycarbonyl, halolower alkyl, hydroxy, cyano, amino, mono- or diloweralkyl amino, lower alkanoylamino, carboxy, carboxylower alkyl, hydroxylower alkyl, carbamoyl, carbamoyloxy, lower alkyl- or phenyl- carbonyl, (loweralkoxy) lower alkoxy, [1-piperidinyl, 4-morpholinyl, 4-lower alkylpiperazinyl, 1-pyrrolidinyl,]OR.sup.8, SR.sup.8, phenyl and phenyl substituted by one or more substituents as hereinbefore defined excepting phenyl; (where R.sup.8 is C.sub.2 -C.sub.6 alkenyl, C.sub.3 -C.sub.10 cycloalkyl, phenyl, phenylloweralkyl or phenyl or phenylloweralkyl each carrying from 1 to 3 substituents on the phenyl selected from lower alkyl, halogen, nitro, haloloweralkyl, hydroxy and lower alkoxy);
- R.sup.1, R.sup.2, R.sup.3 and R.sup.4 independently represent hydrogen, or a substituent as mentioned above in connection with the group R, or any adjacent pair of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 together with the carbon atoms to which they are attached complete a six membered fully unsaturated carbocyclic ring, said ring being optionally substituted by a substituent as defined above in connection with the group R;
- R.sup.5 and R.sup.6 independently represent hydrogen or lower alkyl; n and m independently represent 0 or 1; the term `lower` means a group having 1 to 6 carbon atoms.
- 2. A pharmaceutical composition for treating ulcers or hypersecretion comprising a therapeutically effective amount of a compound of formula ##STR19## or a pharmaceutically acceptable salt thereof wherein --B--B.sup.1 -- represents a chain of formula
- --(CHR.sup.5).sub.n --CHR.sup.6 -- (Ia)
- R represents phenyl, naphthyl or an heteroaryl radical selected from the group pyridyl, thienyl, furyl, thiazolyl, quinolyl, isoquinolyl and indolyl each optionally substituted by not more than three substituents the same or different selected from lower alkylthio, lower alkyl, lower alkoxy, halogen, alkanoyloxy of 2 to 7 carbon atoms, lower alkoxy carbonyl, halolower alkyl, hydroxy, cyano, amino, mono- or di-loweralkyl amino, lower alkanoylamino, carboxy, carboxyloweralkyl, hydroxylower alkyl, carbamoyl, carbamoyloxy, lower alkyl- or phenyl- carbonyl, (loweralkoxy) lower alkoxy, [1-piperidinyl, 4-morpholinyl, 4-loweralkylpiperazinyl, 1-pyrrolidinyl,] OR.sup.8, SR.sup.8, phenyl and phenyl substituted by one or more substituents as hereinbefore defined excepting phenyl; (where R.sup.8 is C.sub.2 -C.sub.6 alkenyl, C.sub.3 -C.sub.10 cycloalkyl, phenyl, phenylloweralkyl or phenyl or phenylloweralkyl each carrying from 1 to 3 substituents on the phenyl selected from lower alkyl, halogen, nitro, haloloweralkyl, hydroxy and lower alkoxy);
- R.sup.1, R.sup.2, R.sup.3 and R.sup.4 independently represent hydrogen or a substituent as mentioned above in connection with the group R, or any adjacent pair of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 together with the carbon atoms to which they are attached complete a six membered fully unsaturated carbocyclic ring, said ring being optionally substituted by a substituent as defined above in connection with the group R;
- R.sup.5 and R.sup.6 independently represent hydrogen or lower alkyl; n and m independently represent 0 or 1; the term `lower` means a group having 1 to 6 carbon atoms, providing that when n is 1 and m is 0 then R is heteroaryl or heteroaryl optionally substituted as defined hereinbefore, and a pharmaceutically acceptable carrier.
- 3. A compound of formula ##STR20## or a pharmaceutically acceptable salt thereof wherein --B--B.sup.1 -- represents a chain of formula
- --(CHR.sup.5).sub.n --CHR.sup.6 -- (Ia)
- R represents phenyl, naphthyl or an heteroaryl radical selected from the group pyridyl, thienyl, furyl, thiazolyl, quinolyl, isoquinolyl and indolyl each optionally substituted by not more than three substituents the same or different selected from lower alkylthio, lower alkyl, lower alkoxy, halogen, alkanoyloxy of 2 to 7 carbon atoms, lower alkoxycarbonyl, halolower alkyl, hydroxy, cyano, amino, mono- or diloweralkyl amino, lower alkanoylamino, carboxy, carboxyloweralkyl, hydroxylower alkyl, carbamoyl, carbamoyloxy, lower alkyl- or phenyl- carbonyl, (loweralkoxy)lower alkoxy, [1-piperidinyl, 4-morpholinyl, 4-loweralkylpiperazinyl, 1-pyrrolidinyl,]OR.sup.8, SR.sup.8, phenyl and phenyl substituted by one or more substituents as hereinbefore defined excepting phenyl; (where R.sup.8 is C.sub.2 -C.sub.6 alkenyl, C.sub.3 -C.sub.10 cycloalkyl, phenyl, phenylloweralkyl or phenyl or phenylloweralkyl each carrying from 1 to 3 substituents on the phenyl selected from lower alkyl, halogen, nitro, haloloweralkyl, hydroxy and lower alkoxy),
- R.sup.1, R.sup.2, R.sup.3 and R.sup.4 independently represent hydrogen, or a substituent as mentioned above in connection with the group R, or any adjacent pair of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 together with the carbon atoms to which they are attached complete a six membered fully unsaturated carbocyclic ring, said ring being optionally substituted by a substituent as defined above in connection with the group R;
- R.sup.5 and R.sup.6 independently represent hydrogen or lower alkyl; n and m independently represent 0 or 1; the term `lower` means a group having 1 to 6 carbon atoms with the provisos
- (i) that when n is 1 and m is 0 then R is heteroaryl or heteroaryl optionally substituted as defined hereinbefore, and (ii) when n is 0 and R.sup.1 and R.sup.2 together with the carbon atoms to which they are attached represent a 6-membered unsaturated carbocyclic ring and R is phenyl or p-nitrophenyl, then m is 1.
- 4. A compound as claimed in claim 3 wherein n is 0.
- 5. A compound as claimed in claim 3 wherein R represents a phenyl, naphthyl, pyridyl, thienyl, furyl, thiazolyl, quinolyl, isoquinolyl or indolyl group each optionally substituted as defined in claim 3.
- 6. A compound as claimed in claim 3 wherein R represents phenyl, pyrid-2-yl or pyrid-3-yl each optionally substituted by one to three groups independently selected from lower alkyl, lower alkoxy, halogen, phenyl, halophenyl, lower alkylphenyl, lower alkoxyphenyl and lower alkylthio.
- 7. A compound as claimed in claim 3 wherein R.sup.2 and R.sup.3 are selected from hydrogen, lower alkyl, alkoxycarbonyl of 2 to 7 carbon atoms, halogen, cyano or lower alkoxy.
- 8. A compound as claimed in claim 3 which is 2,3-dihydro-2-(2-pyridyl)thiazolo[3,2-a]benzimidazole-1-oxide or a pharmaceutically acceptable salt thereof.
- 9. A compound as claimed inb claim 3 which is 6,7-dichloro-2,3-dihydro-2-(6-methylpyrid-3-yl)thiazolo[3,2-a]benzimidazole or a pharmaceutically acceptable salt thereof.
- 10. A compound as claimed in claim 3 which is 2,3-dihydro-6,7-dimethyl-2-(2-pyridyl)-thiazolo[3,2-a]benzimidazole-1-oxide or a pharmaceutically acceptable salt thereof.
- 11. A compound as claimed in claim 3 which is 6-chloro-2,3-dihydro-2-(2-pyridyl)thiazolo[3,2-a]benzimidazole-1-oxide or a pharmaceutically acceptable salt thereof.
- 12. A compound as claimed in claim 3 which is 7-chloro-2,3-dihydro-2-(2-pyridyl)thiazolo[3,2-a]benzimidazole-1-oxide or a pharmaceutically acceptable salt thereof.
- 13. A compound as claimed in claim 3 which is 6,7-dichloro-2,3-dihydro-2-(2-pyridyl)thiazolo[3,2-a]benzimidazole or a pharmaceutically acceptable salt thereof.
- 14. A compound as claimed in claim 3 which is 2,3-dihydro-6-methyl-2-(2-pyridyl)thiazolo[3,2-a]benzimidazole-1-oxide or a pharmaceutically acceptable salt thereof.
- 15. A compound as claimed in claim 3 which is 2,3-dihydro-7methyl-2-(2-pyridyl)thiazolo[3,2-a]-benzimidazole-1-oxide or a pharaceutically acceptable salt thereof.
- 16. A compound as claimed in claim 3 which is 2,3-dihydro-7-methoxycarbonyl-6-methyl-2-(2-pyridyl)thiazolo[3,2-a]benzimidazole-1-oxide or a pharmaceutically acceptable salt thereof.
- 17. A compound as claimed in claim 3 which is 2,3-dihydro-6-methoxycarbonyl-7-methyl-2-(2-pyridyl)thiazolo[3,2-a]benzimidazole-1-oxide or a pharmaceutically acceptable salt thereof.
- 18. A compound as claimed in claim 3 which is 2,3-dihydro-6-methoxycarbonyl-2-(2-pyridyl)thiazolo[3,2-a]-benzimidazole-1-oxide or a pharmaceutically acceptable salt thereof.
- 19. A compound as claimed in claim 3 which is 2,3-dihydro-7-methoxycarbonyl-2-(2-pyridyl)thiazolo[3,2-a]-benzimidazole-1-oxide or a pharmaceutically acceptable salt thereof.
- 20. A compound as claimed in claim 3 which is 2,3-dihydro-2-[2-(6-phenylpyridyl)]thiazolo[3,2-a]benzimidazole; or a pharmaceutically acceptable salt thereof.
- 21. A compound as claimed in claim 3 which is racemic (R*,R*)-2,3-dihydro-2-(4-methoxypyrid-2-yl)thiazolo[3,2-a]benzimidazole-1-oxide or a pharmaceutically acceptable salt thereof.
- 22. A compound as claimed in claim 3, which is 2,3-dihydro-2(2-pyridyl)thiazolo[3,2-a]benzimidazole.
Priority Claims (1)
Number |
Date |
Country |
Kind |
8316645 |
Jun 1983 |
GBX |
|
Parent Case Info
This invention relates to a method for treating ulcers or hypersecretion with heterocyclic compounds more particularly benzimidazoles, to novel compositions comprising benzimidazoles and to the novel compounds themselves and their preparation and is a continuation-in-part of co-pending application Ser. No. 619,870 filed 12th Jun. 1984, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4214089 |
Fenichel et al. |
Jul 1980 |
|
Foreign Referenced Citations (2)
Number |
Date |
Country |
56-18989 |
Feb 1981 |
JPX |
5583710 |
Jan 1982 |
JPX |
Non-Patent Literature Citations (1)
Entry |
Chem. Abstracts, vol. 95 (No. 9) Abst. No. 95: 80996d Aug. 31, 1981. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
619870 |
Jun 1984 |
|